Abir Saraswat
Overview
Explore the profile of Abir Saraswat including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
497
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Verma S, Khurana A, Bosshard P, Kargl A, Singal A, Saraswat A, et al.
Indian J Dermatol Venereol Leprol
. 2025 Feb;
91(2):277-280.
PMID: 39912159
No abstract available.
2.
Satish D, Aurangabadkar S, Tahiliani S, Damisetty R, Tiwari A, D S K, et al.
Cureus
. 2024 Sep;
16(7):e65800.
PMID: 39219884
Acne vulgaris, a prevalent inflammatory skin condition, significantly impacts individuals worldwide, particularly adolescents and adults. Its chronic nature, associated sequelae, and psychosocial impact underscore the substantial burden it poses. Current...
3.
Saraswat A, Dogra S, Shenoy M, Verma S, K S, Ghate S, et al.
Dermatology
. 2024 May;
240(4):671-683.
PMID: 38697027
Super-bioavailable itraconazole (SB ITZ) overcomes the limitations of conventional itraconazole (CITZ) such as interindividual variability and reduced bioavailability. It has been approved for systemic mycoses in Australia and Europe as...
4.
Shenoy M, De A, Shah B, Das A, Saraswat A, Lahiri K, et al.
Indian Dermatol Online J
. 2023 Dec;
14(6):839-843.
PMID: 38099030
Background: Obesity is considered one of the risk factors for dermatophytosis and warrants systemic therapy. Itraconazole is the most commonly used antifungal, but owing to pharmacokinetic challenges, super-bioavailable itraconazole (SITZ)...
5.
Shenoy M, De A, Shah B, Das A, Saraswat A, Lahiri K, et al.
Drug Des Devel Ther
. 2023 Sep;
17:2899-2908.
PMID: 37766823
Introduction: Itraconazole follows non-linear pharmacokinetics and hence is recommended once daily, but in real-world practice, is commonly prescribed as twice daily. Hence, this study aimed to evaluate the efficacy and...
6.
Sachan S, Suvirya S, Yadav K, Gupta P, Saraswat A, Verma P, et al.
Indian J Dermatol Venereol Leprol
. 2023 Jan;
89(4):510-523.
PMID: 36688884
Background Cutaneous mucormycosis has shown a significant upsurge during the COVID-19 pandemic. Due to the rapid progression and high mortality of cutaneous mucormycosis in this context, it is important to...
7.
Rajagopalan M, Saraswat A, Chandrashekar B, Dhar S, Dogra S, Tahiliani S, et al.
Indian Dermatol Online J
. 2022 Oct;
13(5):585-599.
PMID: 36304637
Cyclosporine (CsA) is a calcineurin inhibitor that acts selectively on T cells. It has been used in dermatology since 1997 for its US Food and Drug Administration indication of psoriasis...
8.
Rajagopalan M, Dogra S, Godse K, Kar B, Kotla S, Neema S, et al.
Psoriasis (Auckl)
. 2022 Sep;
12:221-230.
PMID: 36046360
Purpose: The primary objective of the study was to understand the therapeutic inertia in treatment and management of plaque psoriasis among dermatologists, along with determining the preferred treatment choices for...
9.
Rajagopalan M, Dogra S, Saraswat A, Varma S, Banodkar P
Psoriasis (Auckl)
. 2021 Aug;
11:109-122.
PMID: 34430450
Apremilast, an oral phosphodiesterase-4 inhibitor, is approved for use in the management of psoriasis and psoriatic arthritis. Although its efficacy and safety have been well established in clinical studies, in...
10.
Tahiliani S, Saraswat A, Lahiri A, Shah A, Hawelia D, Shah G, et al.
Indian J Dermatol Venereol Leprol
. 2021 Jun;
87(6):800-806.
PMID: 34160163
Background: The prevalence of dermatophytes varies with season, geographical area, socio-economic factors and effective management strategies. Aims: The aim of the study was to assess the prevalence of pathogenic dermatophytes,...